WEDNESDAY, 16th OCTOBER 2019 COMMENCING 10:30 AM
AT THE COPTHORNE HOTEL CARDIFF, COPTHORNE WAY,
CULVERHOUSE CROSS, CARDIFF CF5 6DH

AGENDA

1. Welcome and introduction

2. Apologies

3. Declarations of interest

4. Minutes of previous meeting 1/AWMSG/1019

5. Chairman’s report (verbal update)

6. Appraisal 1: Limited Submission
   Zanamivir (Dectova®) for the treatment of complicated and potentially
   life-threatening influenza A or B virus infection in adult and paediatric
   patients (aged ≥6 months) when:
   The patient’s influenza virus is known or suspected to be resistant to
   anti-influenza medicinal products other than zanamivir, and/or other
   anti-viral medicinal products for treatment of influenza, including
   inhaled zanamivir, are not suitable for the individual patient. Dectova
   should be used in accordance with official guidance 2/AWMSG/1019
   Appendices

7. Appraisal 2: Limited Submission
   Glecaprevir/pibrentasvir (Maviret®) for the treatment of chronic
   hepatitis C virus infection in adolescents aged 12 to < 18 years 3/AWMSG/1019
   Appendices

8. Endocrine management of gender dysphoria in adults:
   prescribing guidance for non-specialist practitioners 4/AWMSG/1019

9. Medicine Identified as a Low Priority for Funding in NHS Wales –
   Paper 1 (Update to section on liothyronine) 5/AWMSG/1019

10. NICE in Wales – Dr Julie Vile, Implementation Facilitator, NICE
    Field Team (Wales)

   Date of next meeting – Wednesday, 13th November 2019 in Cardiff